Click here to take the survey on Improving PMS outcomes.
Canadian researchers have proposed six criteria that must be met for a disease-modifying therapy (DMT) to be effective in progressive multiple sclerosis (Yong & Yong. Nat Rev Neurol 2022;18:40-55). Over a dozen DMTs are currently available but they generally have limited effectiveness in slowing the neurodegeneration that underlies disability progression.
A number of new studies have provided data on the long-term safety and efficacy of high-efficacy disease-modifying therapies in MS. The data were presented at the American Academy of Neurology (AAN) annual meeting, held April 2-7 in Seattle, Washington. The following is a summary of key studies. Read More
Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 5 Edition
April 4 Edition
SPMS undertreated
NEDA not preditive of disability in RMS
Emerging concepts: spinal cord reserve
Thalamic volume affects cognitive recovery
Alemtuzumab in PMS
Clinical practice Read More
Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 4 Edition
COVID-19 boosters
MS and pregnancy
First CBT trial for MS fatigue
Clinical practice Read More
Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.
April 6 Edition
April 5 Edition
DMTs and vaccine response
Age and outcomes
Biomarkers
Radiologically isolated syndrome (RIS)
Clinical practice Read More